首页> 外文OA文献 >Severe aplastic anemia during osimertinib treatment in a non-small cell lung cancer patient harboring EGFR T790M mutation

【2h】

Severe aplastic anemia during osimertinib treatment in a non-small cell lung cancer patient harboring EGFR T790M mutation

机译：患有EGFR T790M突变的非小细胞肺癌患者中的严重缓解性贫血治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Seo Ree Kim; Jihyun Han; Jae-Ho Yoon; Jeong-Oh Kim; Jin hyoung Kang;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation [J] . Go Makimoto, Tatsuya Nishi, Keita Kawakado, Internal medicine. . 2020,第17期

机译：在患有EGFR T790M突变的非小细胞肺癌治疗的患者患者中患有OSIMERTINIB的荨麻疹后，用OSIMERTINIB进行成功的脱敏治疗
2. Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI [J] . Yusuke Okuma, Yukio Hosomi Journal of Thoracic Disease . 2017,第3期

机译：Osimertinib用于高级非小细胞肺癌，涉及EGFR突变外显子20 T790M，获得第一或第二代EGFR-TKI的抗性突变
3. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation [J] . Auliac Jean Bernard, Perol Maurice, Planchard David, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2019,第期

机译：口服尼斯在预处理患者预期非小细胞肺癌患者患有EGFR T790M突变的实际效果
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. The cost effectiveness of screening for early stage lung cancer and the testing and treatment of molecular subgroups among non-small cell lung cancer patients in the province of ontario, canada [D] . Thao, Mallory. 2014

机译：加拿大安大略省非小细胞肺癌患者早期肺癌筛查的成本效益及分子亚群的检测和治疗
6. Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M acquired resistant mutation for first- or second-generation EGFR-TKI [O] . Yusuke Okuma, Yukio Hosomi 2017

机译：奥西替尼用于携带EGFR突变外显子20 T790M的晚期非小细胞肺癌第一代或第二代EGFR-TKI的获得性耐药突变
7. Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI [O] . Yusuke Okuma, Yukio Hosomi 2017

机译：Osimertinib用于高级非小细胞肺癌，涉及EGFR突变外显子20 T790M，获得第一或第二代EGFR-TKI的抗性突变

Severe aplastic anemia during osimertinib treatment in a non-small cell lung cancer patient harboring EGFR T790M mutation

著录项

引文网络

相似文献

相关主题

期刊订阅